Analisis Karakteristik Pasien Tuberkulosis Paru di Puskesmas Cibaduyut Kidul Tahun 2024-2025

Analysis of Pulmonary Tuberculosis Patient Characteristics at Puskesmas Cibaduyut Kidul in 2024-2025

Authors

  • Feggy Yustika Sitinjak Universitas Padjadjaran Author
  • Keri Lestari Author
  • Ade Zuhrotun Author

DOI:

https://doi.org/10.30872/jsk.v7i2.1027

Keywords:

Tuberkulosis, Tuberkulosis Paru, tuberkulosis resistan obat, Mycobacterium tuberculosis

Abstract

Tuberkulosis (TB) masih menjadi masalah kesehatan yang signifikan di Indonesia, dengan peningkatan insiden kasus yang dilaporkan, terutama pada tahun 2024-2025. Studi ini mengkaji karakteristik pasien tuberkulosis paru di Puskesmas Cibaduyut Kidul, dengan fokus pada demografi pasien dan hasil pengobatan. Sebanyak 116 pasien dilibatkan, terdiri dari 54 pasien pada tahun 2024 (46,55%) dan 62 pasien pada tahun 2025 (53,45%). Pasien laki-laki mencapai 54,31%, dengan kelompok usia terdampak terbesar adalah anak-anak di bawah 18 tahun, yaitu sebesar 34,48%. Penelitian menunjukkan bahwa sebagian besar pasien mendapatkan pengobatan yang efektif, dengan 35,34% mencapai pemulihan total dan 31,90% menyelesaikan seluruh protokol pengobatan. Meskipun demikian, 28,45% pasien tetap menjalani pengobatan, dan 2 pasien (1,72%) meninggal dunia. Lebih lanjut, 2,59% pasien menerima diagnosis tuberkulosis resistan obat (TB RO) yang direvisi. Hasil penelitian menunjukkan prevalensi tuberkulosis yang substansial di kalangan demografi yang lebih muda, disertai dengan kemajuan signifikan dalam efikasi pengobatan, meskipun terhambat oleh masalah resistensi obat dan kepatuhan terhadap protokol pengobatan. Temuan ini menggarisbawahi perlunya peningkatan pencegahan tuberkulosis, diagnosis dini, dan edukasi pasien untuk meningkatkan luaran pengobatan di lingkungan pelayanan kesehatan primer. 

References

[1] J. W. Saelens, G. Viswanathan, dan D. M. Tobin, “Mycobacterial Evolution Intersects With Host Tolerance,” 2019. doi: 10.3389/fimmu.2019.00528.

[2] K. Basalingappa et al., “Tuberculosis – An overview,” Indian J. Microbiol. Res., 2021, doi: 10.18231/j.ijmr.2021.019.

[3] G. Davidson et al., “Overview of Tuberculosis: Causes, Symptoms and Risk Factors,” Asian J. Res. Infect. Dis., 2024, doi: 10.9734/ajrid/2024/v15i9370.

[4] B. N. P. Kumar et al., “Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica–Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer,” Mol. Pharm., vol. 15, no. 7, hal. 2698–2713, Jul 2018, doi: 10.1021/acs.molpharmaceut.8b00218.

[5] C. A. McCarthy, D. Y. Zemlyanov, A. M. Crean, dan L. S. Taylor, “Comparison of Drug Release and Adsorption under Supersaturating Conditions for Ordered Mesoporous Silica with Indomethacin or Indomethacin Methyl Ester,” Mol. Pharm., vol. 17, no. 8, hal. 3062–3074, Agu 2020, doi: 10.1021/acs.molpharmaceut.0c00489.

[6] G. Migliori, C. Ong, L. Petrone, L. D’Ambrosio, R. Centis, dan D. Goletti, “The definition of tuberculosis infection based on the spectrum of tuberculosis disease,” Breathe, vol. 17, 2021, doi: 10.1183/20734735.0079-2021.

[7] K. Zaman, “Tuberculosis: A Global Health Problem,” J. Health. Popul. Nutr., vol. 28, hal. 111–113, 2010, doi: 10.3329/jhpn.v28i2.4879.

[8] World Health Organization, Global tuberculosis report 2025. 2025.

[9] Kementerian Kesehatan Republik Indonesia, Profil Kesehatan. 2024.

[10] F. Fahdhienie, M. Mudatsir, T. Abidin, dan N. Nurjannah, “Risk factors of pulmonary tuberculosis in Indonesia: A case-control study in a high disease prevalence region,” Narra J, vol. 4, 2024, doi: 10.52225/narra.v4i2.943.

[11] W. Bai dan E. Ameyaw, “Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021,” BMC Public Health, vol. 24, 2024, doi: 10.1186/s12889-023-17495-6.

[12] H. Li, C. Chee, T. Geng, A. Pan, dan W. Koh, “Joint associations of multiple lifestyle factors with risk of active tuberculosis in the population: the Singapore Chinese Health Study.,” Clin. Infect. Dis., 2021, doi: 10.1093/cid/ciab935.

[13] R. Duarte et al., “Tuberculosis, social determinants and co-morbidities (including HIV).,” Pulmonology, vol. 24 2, hal. 115–119, 2017, doi: 10.1016/j.rppnen.2017.11.003.

[14] J. Franco et al., “Diabetes as a risk factor for tuberculosis disease,” Cochrane Database Syst. Rev., vol. 2024, 2024, doi: 10.1002/14651858.cd016013.pub2.

[15] P. Narasimhan, J. Wood, C. MacIntyre, dan D. Mathai, “Risk Factors for Tuberculosis,” Pulm. Med., vol. 2013, 2013, doi: 10.1155/2013/828939.

[16] Y. Gelaw, Z. Getaneh, dan M. Melku, “Anemia as a risk factor for tuberculosis: a systematic review and meta-analysis,” Environ. Health Prev. Med., vol. 26, 2021, doi: 10.1186/s12199-020-00931-z.

[17] E. Groenweghe et al., “Outbreak of Multidrug-Resistant Tuberculosis — Kansas, 2021–2022,” 2023. doi: 10.15585/mmwr.mm7235a4.

[18] F. Mhimbira et al., “Prevalence and Clinical Relevance of Helminth Co-Infections Among Tuberculosis Patients in Urban Tanzania,” 2017. doi: 10.1371/journal.pntd.0005342.

[19] G. Durgeshwar et al., “Comparison of Diagnostic Yield and Complications in Ultrasound-Guided Closed Pleural Biopsy Versus Thoracoscopic Pleural Biopsy in Undiagnosed Exudative Pleural Effusion,” 2022. doi: 10.7759/cureus.23809.

[20] Kementerian Kesehatan Republik Indonesia, “PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 67 TAHUN 2016,” 2016.

[21] E. Osei, S. A. Oppong, dan J. Der, “Trends of Tuberculosis Case Detection, Mortality and Co-Infection With HIV in Ghana: A Retrospective Cohort Study,” 2020. doi: 10.1371/journal.pone.0234878.

[22] W. W. Aung et al., “Pyrazinamide Resistance Among Multidrug-Resistant Mycobacterium Tuberculosis Clinical Isolates in Myanmar,” 2018. doi: 10.1128/aac.01984-17.

[23] E. E. Evans et al., “Long Term Outcomes of Patients With Tuberculous Meningitis: The Impact of Drug Resistance,” 2022. doi: 10.1371/journal.pone.0270201.

[24] E. Paikray, M. Pattnaik, V. Mishra, P. A. Abhisek, S. S. Pradhan, dan A. Rout, “Evaluation of Health-Related Quality of Life and Adherence Among Pre-Extensively Drug-Resistant Tuberculosis Patients Receiving Either Bedaquiline or Delamanid Regimen at a Teaching Hospital in Eastern India,” J. Fam. Med. Prim. Care, vol. 13, no. 10, hal. 4684–4692, 2024, doi: 10.4103/jfmpc.jfmpc_572_24.

[25] N. Aitambayeva et al., “A Systematic Review of Tuberculosis Stigma Reduction Interventions,” Healthcare, vol. 13, no. 15, hal. 1846, 2025, doi: 10.3390/healthcare13151846.

[26] M. Mengesha, A. Tadesse, T. Gari, dan A. Zebdewos, “Determinants of Drug Resistant Tuberculosis Among Tuberculosis Patients on Treatment in Gedeo Zone Public Healthcare Facilities, Southern Ethiopia, 2025. Unmatched Case‒control Study.,” 2026. doi: 10.21203/rs.3.rs-8915478/v1.

[27] T. A. Jhaveri et al., “Barriers to Engagement in the Care Cascade for Tuberculosis Disease in India: A Systematic Review of Quantitative Studies,” 2024. doi: 10.1371/journal.pmed.1004409.

[28] S. J. Saabdulla, S. Baybayan, dan M. Asiri, “Treatment Adherence Among Patients With Pulmonary Tuberculosis in Jolo,” 2024. doi: 10.62596/1et6em44.

[29] F. Xie et al., “Evidence‐Based Summary on Medication Adherence Management for Adult Tuberculosis Patients With Multi‐Dimensional Strategies and Practice Framework,” 2025. doi: 10.1111/jep.70280.

[30] K. Dixit, “Understanding Psychosocial and Economic Barriers to Develop Innovative People-Centered Models of Tuberculosis Care in Nepal,” 2024. doi: 10.69622/26977144.v1.

[31] J. N. Sekandi et al., “Using a Mobile Health Intervention (DOT Selfie) With Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda: Protocol for a Randomized Controlled Trial,” 2021. doi: 10.2196/18029.

[32] N. F. Baloyi dan Z. M. Manyisa, “Patients’ Perceptions on the Factors Contributing to Non-Conversion After Two Months of Tuberculosis Treatment at Selected Primary Healthcare Facilities in the Ekurhuleni Health District, South Africa,” 2022. doi: 10.2174/18749445-v15-e2208291.

[33] R. B. Pratiwi, “Depression Among Tuberculosis Patients and Its Association With Medication Adherence of Anti-Tuberculosis Drugs Literature Review,” 2024. doi: 10.56338/mppki.v7i7.5337.

[34] C. C. Mendes, R. J. G. Unger, T. C. de Araújo-Jorge, dan A. C. C. Carvalho, “Tuberculosis in Adolescence: An Integrative Review Focusing on Patient-Centered Care,” Rev. Paul. Pediatr., vol. 42, 2024, doi: 10.1590/1984-0462/2024/42/2023027.

[35] A. Setiyadi, U. Noviana, E. N. Sholikhah, A. Akhmadi, dan H. Mufarokhah, “Community Empowerment Through Cadres in the Tuberculosis Program: A Scoping Review,” 2025. doi: 10.18502/ijph.v54i7.19113.

Downloads

Published

2026-05-28

Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/jskff/public_html/plugins/generic/citations/CitationsPlugin.php on line 68

How to Cite

[1]
F. Y. Sitinjak, Keri Lestari, and A. Zuhrotun, “Analisis Karakteristik Pasien Tuberkulosis Paru di Puskesmas Cibaduyut Kidul Tahun 2024-2025: Analysis of Pulmonary Tuberculosis Patient Characteristics at Puskesmas Cibaduyut Kidul in 2024-2025”, J. Sains. Kes, vol. 7, no. 2, pp. 104–110, May 2026, doi: 10.30872/jsk.v7i2.1027.

Similar Articles

61-70 of 180

You may also start an advanced similarity search for this article.